Regional overviews

celebrating 20 years China

STATISTICS  
Number of products launched: 0 (2017: 0)
IMS value of pipeline as at 30 June 2018 anticipated to be launched in:  
0 – 2 years USD0 million
3 – 5 years USD13 million
Number of product recalls: 0 (2017: 0)
Average staff turnover: 25,9% (2017: 0,0%)
Number of work-related fatalities: 0 (2017: 0)
Number of permanent employees:  
Number of permanent employees:  
 

Aspen China is set to become a significant contributor to the Group performance with a product range comprising the recently acquired Thrombosis and Anaesthetic Brands as well as some smaller global brands.

Contribution to Group revenue

Revenue - R'million 2018 2017 (CER) % change
Commercial Pharmaceuticals 2 415 1 748 38
Anaesthetics 1 779 1 435 24
Thrombosis 616 266 >100
High Potency & Cytotoxics 20 47 (57)
Nutritionals 65 100
Total 2 480 1 748 42
 
  • The China pharmaceutical sector was valued at USD83 billion as at 31 December 2017.
  • China made up 38,9% of the total Asian pharmaceutical sector as at 31 December 2017.
Source: December 2017 IMS